 |
Christopher S. Bond (ed). Examining state & federal oversight to ensure the safety & quality of drug compounding -- the process of mixing, combining, or altering ingredients to create a customized medication for an individual patient -- by pharmacies. Witnesses: Janet Heinrich, DrPH, RN, Dir. of Health Care-Public Health Issues, Gen. Accounting Office (GAO); Steven Galson, M.D., MPH, Deputy Dir., Center for Drug Evaluation & Research, U.S. Food & Drug Admin. (FDA); Sarah L. Sellers, PHARM.D, Exec. Dir., The Center for Pharmaceutical Safety; Daniel A. Herbert, RPh, Pres. Elect, Amer. Pharmacists Assoc.; Kevin Kindake, Exec. Dir., Missouri Board of Pharmacy; & William Kennedy, owner, Nephron Pharmaceuticals Corp.
|
|
|
